Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Indusatumab vedotin. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Indusatumab vedotin. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Indusatumab vedotin. |
| Estrone | Estrone may increase the thrombogenic activities of Indusatumab vedotin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Indusatumab vedotin. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Indusatumab vedotin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Indusatumab vedotin. |
| Mestranol | Mestranol may increase the thrombogenic activities of Indusatumab vedotin. |
| Estriol | Estriol may increase the thrombogenic activities of Indusatumab vedotin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Indusatumab vedotin. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Indusatumab vedotin. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Indusatumab vedotin. |
| Tibolone | Tibolone may increase the thrombogenic activities of Indusatumab vedotin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Indusatumab vedotin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indusatumab vedotin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Indusatumab vedotin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Indusatumab vedotin. |
| Zeranol | Zeranol may increase the thrombogenic activities of Indusatumab vedotin. |
| Equol | Equol may increase the thrombogenic activities of Indusatumab vedotin. |
| Promestriene | Promestriene may increase the thrombogenic activities of Indusatumab vedotin. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Indusatumab vedotin. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Indusatumab vedotin. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Indusatumab vedotin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Indusatumab vedotin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Indusatumab vedotin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Indusatumab vedotin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Indusatumab vedotin. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Indusatumab vedotin. |
| Formononetin | Formononetin may increase the thrombogenic activities of Indusatumab vedotin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Indusatumab vedotin. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Indusatumab vedotin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indusatumab vedotin. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Indusatumab vedotin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Indusatumab vedotin. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Indusatumab vedotin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indusatumab vedotin. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Indusatumab vedotin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Indusatumab vedotin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Indusatumab vedotin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Indusatumab vedotin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Indusatumab vedotin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Indusatumab vedotin. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Indusatumab vedotin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indusatumab vedotin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Indusatumab vedotin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indusatumab vedotin. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Indusatumab vedotin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Indusatumab vedotin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indusatumab vedotin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Indusatumab vedotin. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Indusatumab vedotin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Indusatumab vedotin. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indusatumab vedotin. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Indusatumab vedotin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Indusatumab vedotin. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Indusatumab vedotin. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Indusatumab vedotin. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Indusatumab vedotin. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Indusatumab vedotin. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Indusatumab vedotin. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Indusatumab vedotin. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Indusatumab vedotin. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Indusatumab vedotin. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Indusatumab vedotin. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Indusatumab vedotin. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Indusatumab vedotin. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Indusatumab vedotin. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Indusatumab vedotin. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Indusatumab vedotin. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Indusatumab vedotin. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Indusatumab vedotin. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Indusatumab vedotin. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Indusatumab vedotin. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Indusatumab vedotin. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Indusatumab vedotin. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Indusatumab vedotin. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Indusatumab vedotin. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Indusatumab vedotin. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Indusatumab vedotin. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Indusatumab vedotin. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Indusatumab vedotin. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Indusatumab vedotin. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Indusatumab vedotin. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Indusatumab vedotin. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Indusatumab vedotin. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Indusatumab vedotin. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Indusatumab vedotin. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Indusatumab vedotin. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Indusatumab vedotin. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Indusatumab vedotin. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Indusatumab vedotin. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Indusatumab vedotin. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Indusatumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Indusatumab vedotin. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Indusatumab vedotin. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Indusatumab vedotin. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Indusatumab vedotin. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Indusatumab vedotin. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Indusatumab vedotin. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Indusatumab vedotin. |